Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

substipharm - ivermectin 3 mg - tablet - 3 mg - ivermectin 3 mg - ivermectin

Ireland - English - HPRA (Health Products Regulatory Authority)

substipharm - nystatin - oral suspension - 100,000 international unit(s)/millilitre - antibiotics; nystatin

Ireland - English - HPRA (Health Products Regulatory Authority)

substipharm developpement - alverine citrate - capsules hard - 60 milligram

European Union - English - EMA (European Medicines Agency)

substipharm - prasugrel - acute coronary syndrome; angina, unstable; myocardial infarction - antithrombotic agents - efient, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (i.e. unstable angina, non-st-segment-elevation myocardial infarction [ua / nstemi] or st-segment-elevation myocardial infarction [stemi]) undergoing primary or delayed percutaneous coronary intervention (pci).

European Union - English - EMA (European Medicines Agency)

substipharm - raloxifene hydrochloride - osteoporosis, postmenopausal - sex hormones and modulators of the genital system, - evista is indicated for the treatment and prevention of osteoporosis in post-menopausal women. a significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. when determining the choice of evista or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.